Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Cardiology Update from the 2008 ACC Annual Meeting
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Overview
Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Personalizing Care Within the RCC Treatment Paradigm
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
NYHA FC and Finerenone Response: Clinical Trial Insights
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?